Kevin Norrett

Mr. Norrett brings over two decades of experience across commercial strategy, business operations and corporate development for both established and emerging biotechnology companies. Most recently, he served as Chief Business Officer of Sierra Oncology. There, he led commercial operations and corporate development and communications and completed the $1.9 billion acquisition by GSK. Prior to Sierra Oncology, Mr. Norrett was Chief Commercial Officer at Angion Biomedica, setting commercial strategy and positioning for its pipeline and its successful IPO. Previously, he served as Vice President of Marketing, Market Access and Commercial Operations at Aimmune Therapeutics, acquired by Nestle Health Science, where he built commercial operations for the launch of Palforzia®, the first approved therapy for pediatric peanut allergy. Prior to joining Aimmune, Mr. Norrett was Vice President, Market Access and Commercial Development at ZS Pharma, acquired by AstraZeneca for $2.7 billion. Mr. Norrett also held increasingly senior commercial leadership roles at Exelixis and Genentech, where he launched multiple products across oncology and rare disease. Kevin also served as an Associate in SG Cowen’s Health Care Investment Banking Group, closing over 20 transactions worth over $2 billion. Mr. Norrett earned an M.B.A. from the Haas School of Business at the University of California, Berkeley, an M.S. in Biochemistry and Molecular Biology from University of California, Los Angeles and a B.S. in Biological Sciences from the University of California, Davis.